Orthocell Ltd (ASX: OCC) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Orthocell Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $101.06 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 194.34 million
Earnings per share -0.047
Dividend per share N/A
Year To Date Return 12.22%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Orthocell Ltd (ASX: OCC)
Latest News

OCC ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Orthocell Ltd

Orthocell Ltd is a regenerative medicine company. The company is engaged in the development and commercialisation of cell therapies and related technologies. Its product includes CelGro is a naturally derived collagen medical device for tissue repair and Ortho-ATI is a first-in-class cell therapy for the treatment of chronic tendon injuries.

OCC Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
01 Dec 2021 $0.52 $0.01 1.94% 176,134 $0.52 $0.53 $0.52
30 Nov 2021 $0.52 $0.01 1.98% 197,930 $0.50 $0.52 $0.50
29 Nov 2021 $0.51 $-0.01 -1.96% 248,300 $0.50 $0.51 $0.50
26 Nov 2021 $0.51 $-0.02 -3.77% 146,432 $0.53 $0.53 $0.51
25 Nov 2021 $0.53 $0.01 1.92% 137,028 $0.52 $0.53 $0.52
24 Nov 2021 $0.52 $0.00 0.00% 53,498 $0.52 $0.53 $0.52
23 Nov 2021 $0.52 $0.01 1.94% 83,183 $0.52 $0.52 $0.52
22 Nov 2021 $0.52 $-0.01 -1.92% 19,937 $0.52 $0.52 $0.51
19 Nov 2021 $0.52 $-0.01 -1.89% 50,924 $0.53 $0.53 $0.52
18 Nov 2021 $0.53 $-0.01 -1.85% 144,044 $0.54 $0.54 $0.53
17 Nov 2021 $0.54 $0.01 1.87% 322,629 $0.54 $0.55 $0.54
16 Nov 2021 $0.54 $0.01 1.89% 223,064 $0.53 $0.54 $0.53
15 Nov 2021 $0.53 $0.04 8.08% 263,720 $0.50 $0.54 $0.50
12 Nov 2021 $0.50 $0.00 0.00% 65,114 $0.50 $0.51 $0.50
11 Nov 2021 $0.50 $-0.01 -2.00% 56,961 $0.50 $0.50 $0.49
10 Nov 2021 $0.50 $0.00 0.00% 49,067 $0.50 $0.50 $0.50
09 Nov 2021 $0.50 $-0.01 -1.96% 162,490 $0.51 $0.51 $0.50
08 Nov 2021 $0.51 $0.01 1.98% 223,057 $0.50 $0.52 $0.50
05 Nov 2021 $0.51 $-0.01 -1.94% 87,328 $0.52 $0.52 $0.50
04 Nov 2021 $0.52 $0.00 0.00% 161,505 $0.52 $0.53 $0.52
03 Nov 2021 $0.52 $-0.02 -3.74% 100,278 $0.54 $0.54 $0.51
02 Nov 2021 $0.54 $0.00 0.00% 52,540 $0.53 $0.54 $0.53

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
23 Sep 2021 Stewart Washer Sell 417 $199,871
On-market trade.
23 Sep 2021 Paul Anderson Sell 717 $343,595
On-market trade.
23 Sep 2021 Paul Anderson Sell 435 $208,356
On-market trade.
06 Apr 2021 Lars Lidgren Buy 9 $4,860
Off-market trade.
22 Jan 2021 Qi Zhou Issued 93 $53,587
Exercise of options.
22 Jan 2021 Qi Zhou Exercise 300 $172,260
Exercise of options.
22 Jan 2021 Paul Anderson Exercise 3 $1,808,730
Exercise of options.
22 Jan 2021 Paul Anderson Issued 265 $152,319
Exercise of options.
22 Jan 2021 Paul Anderson Issued 717 $412,159
Exercise of options.
22 Jan 2021 Matthew (Matt) Callahan Exercise 1 $1,062,270
Exercise of options.
22 Jan 2021 Matthew (Matt) Callahan Issued 577 $331,519
Exercise of options.
22 Jan 2021 Stewart Washer Exercise 1 $1,062,270
Exercise of options.
22 Jan 2021 Stewart Washer Issued 577 $331,519
Exercise of options.
22 Jan 2021 Lars Lidgren Issued 93 $53,759
Exercise of options.
22 Jan 2021 Lars Lidgren Exercise 300 $172,260
Exercise of options.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Matthew (Matt) Callahan Non-Executive Director Feb 2020
Mr Callahan is a founding director of Orthocell. Mr Callahan is an experienced life sciences executive based in Philadelphia, USA. He has been the founding CEO or Executive Director of pharmaceutical and health tech companies including iCeutica Inc, Churchill Pharma Inc, Dimerix Biosciences, Emyria Ltd and Botanix Pharmaceuticals. He has led the development of four products that have received FDA approval and he has more than 25 years legal, IP and investment management experience. Mr Callahan has worked as an investment director for two venture capital firms investing in life sciences, clean technology and other sectors, and was General Manager and General Counsel with Australian listed technology and licensing company iPernica (Nearmap).
Dr Stewart James Washer Executive ChairmanExecutive Director Apr 2014
Dr Washer has 25 years of CEO and board experience in medical and agri-food biotech companies. He is Chairman of Emyria Ltd, director of Botanix Pharmaceuticals Ltd and current Director of Cynata Therapeutics Ltd. Stewart has held a number of Board positions in the past, including Chairman of Hatchtech Pty Ltd and was a director of iCeutica that was sold to a US Pharma. He was also a Senator with Murdoch University and was a Director of AusBiotech Ltd.
Professor Lars Lidgren Non-Executive Director Dec 2007
Professor Lidgren has authored and co-authored over 450 original publications and has more than 150 patents/applications. He was spokesman for Biomaterials in the Nordic Orthopaedic Society, Chairman for the Swedish National Knee Register, Director of the National Board of Health and Welfare, Musculoskeletal Competence Centre, and member of several editorial boards. Professor Lidgren initiated and has led the UN ratified Bone and Joint Decade and founded Scandimed. Professor Lidgren is the inventor, founder and board member of Bone Support and Director of Curando Nordic.
Mr Qi Xiao Zhou Non-Executive Director Nov 2012
Mr Zhou has over 16 years' experience within China as a senior business manager & executive. Mr Zhou is the founding CEO of Shenzhen Lightning Digital Technology Co Ltd. Mr Zhou has experience within the public markets in Hong Kong, China & Taiwan and brings to the Board business management & development experience. Mr Zhou also has connections and experience in the licensing of technologies into the Asian region.
Mr Paul Frederick Anderson Managing Director Mar 2006
Mr Anderson has over 20 years' experience in the medical device and regenerative medicine fields with experience in bridging the gap between research and clinical practice in the development of emerging medical technologies. He also has experience in the establishment of GMP manufacturing facilities and scale-up activities for cell therapies and biological medical devices, and the associated regulatory filings. Mr Anderson has a track record with over 16 years' experience in CEO and board roles. His knowledge of the regenerative medicine fields compliments his insight and know-how in taking biological therapies from research to clinical applications and market introduction.
Ms Leslie Wise Executive Director Jun 2020
Ms Wise is an experienced board member with track record in medical device technologies and the life science industry including regulatory and market access strategies and commercialisation of Large and SMEs to the next level of growth and expansion. Leslie's 18-year record of accomplishment has given her a range of experience including market access, business strategy, product development, clinical trial design, reimbursement strategy and global commercialisation.
Mr Simon Lee Robertson Company Secretary Nov 2012
-
Simon Lee Robertson Company Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Ming Hao Zheng & Fan Ting 7,564,860 3.96%
Mr Paul Frederick Anderson & Ms Nicole Jane Telford 6,403,335 3.35%
Mr Qbdao Zhou 5,996,241 3.14%
Mr Jia Xun Xu 5,168,276 2.70%
National Nominees Limited 3,009,595 1.58%
Citicorp Nominees Pty Limited 2,193,213 1.15%
Dr John Clifford Philpott 1,560,216 0.82%
Dr John Clifford Philpott & Mrs Rebecca Anne Philpott 1,381,700 0.72%
Mr Patrick John McHale 1,180,000 0.62%
Mr Vance Clark Moore 1,155,000 0.60%
BNP Paribas Nominees Pty Ltd 1,148,323 0.60%
Bond Street Custodians Limited 1,100,000 0.58%
Mr Scoff Anthony Walden 1,080,000 0.57%
Ms Nominees Ply Ltd 1,042,816 0.55%
HSBC Custody Nominees (Australia) Limited 1,007,144 0.53%
Gwalla Pty Ltd 1,000,000 0.52%
Stewart Washer & Pairizia Washer 994,783 0.52%
Mr Paul John Van Dyk 957,000 0.50%
Murdoch Ventures tly Ltd 923,841 0.48%
Algora AB 870,716 0.46%

Profile

since

Note